Guidelines by the National Institute for Health and Care Excellence,
1 American Psychological Association,
2 and American Psychiatric Association,
3 as well as the German National Clinical Practice Guideline
4 recommend use of a single, non–monoamine oxidase inhibitor antidepressant as initial treatment in severe depression. Despite a host of antidepressant agents, response rates to initial antidepressant monotherapy hover at 60%, and remissions occur in only up to 40% of patients, even after 12 to 24 weeks of treatment.
5